Julie Ahn1, Justin A Bishop1, Belinda Akpeng2, Sara I Pai2, Simon R A Best3. 1. Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 2. Harvard Medical School, Boston, Massachusetts, USA. 3. Johns Hopkins School of Medicine, Baltimore, Maryland, USA sbest2@jhmi.edu.
Abstract
OBJECTIVE: Identifying effective treatment for papillomatosis is limited by a lack of animal models, and there is currently no preclinical model for testing potential therapeutic agents. We hypothesized that xenografting of papilloma may facilitate in vivo drug testing to identify novel treatment options. METHODS: A biopsy of fresh tracheal papilloma was xenografted into a NOD-scid-IL2Rgamma(null) (NSG) mouse. RESULTS: The xenograft began growing after 5 weeks and was serially passaged over multiple generations. Each generation showed a consistent log-growth pattern, and in all xenografts, the presence of the human papillomavirus (HPV) genome was confirmed by polymerase chain reaction (PCR). Histopathologic analysis demonstrated that the squamous architecture of the original papilloma was maintained in each generation. In vivo drug testing with bevacizumab (5 mg/kg i.p. twice weekly for 3 weeks) showed a dramatic therapeutic response compared to saline control. CONCLUSION: We report here the first successful case of serial xenografting of a tracheal papilloma in vivo with a therapeutic response observed with drug testing. In severely immunocompromised mice, the HPV genome and squamous differentiation of the papilloma can be maintained for multiple generations. This is a feasible approach to identify therapeutic agents in the treatment of recurrent respiratory papillomatosis.
OBJECTIVE: Identifying effective treatment for papillomatosis is limited by a lack of animal models, and there is currently no preclinical model for testing potential therapeutic agents. We hypothesized that xenografting of papilloma may facilitate in vivo drug testing to identify novel treatment options. METHODS: A biopsy of fresh tracheal papilloma was xenografted into a NOD-scid-IL2Rgamma(null) (NSG) mouse. RESULTS: The xenograft began growing after 5 weeks and was serially passaged over multiple generations. Each generation showed a consistent log-growth pattern, and in all xenografts, the presence of the human papillomavirus (HPV) genome was confirmed by polymerase chain reaction (PCR). Histopathologic analysis demonstrated that the squamous architecture of the original papilloma was maintained in each generation. In vivo drug testing with bevacizumab (5 mg/kg i.p. twice weekly for 3 weeks) showed a dramatic therapeutic response compared to saline control. CONCLUSION: We report here the first successful case of serial xenografting of a tracheal papilloma in vivo with a therapeutic response observed with drug testing. In severely immunocompromised mice, the HPV genome and squamous differentiation of the papilloma can be maintained for multiple generations. This is a feasible approach to identify therapeutic agents in the treatment of recurrent respiratory papillomatosis.
Authors: Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid Journal: Neoplasia Date: 2013-10 Impact factor: 5.715
Authors: Simon R Best; Aaron D Friedman; Tali Landau-Zemer; Anca M Barbu; James A Burns; Mason W Freeman; Yuan-Di Halvorsen; Robert E Hillman; Steven M Zeitels Journal: Ann Otol Rhinol Laryngol Date: 2012-09 Impact factor: 1.547
Authors: Hang Yuan; Scott Myers; Jingang Wang; Dan Zhou; Jennifer A Woo; Bhaskar Kallakury; Andrew Ju; Michael Bazylewicz; Yvonne M Carter; Christopher Albanese; Nazaneen Grant; Aziza Shad; Anatoly Dritschilo; Xuefeng Liu; Richard Schlegel Journal: N Engl J Med Date: 2012-09-27 Impact factor: 91.245
Authors: Steven M Zeitels; Anca M Barbu; Tali Landau-Zemer; Gerardo Lopez-Guerra; James A Burns; Aaron D Friedman; Mason W Freeman; Yuan-Di Halvorsen; Robert E Hillman Journal: Ann Otol Rhinol Laryngol Date: 2011-10 Impact factor: 1.547
Authors: Vincent C Daniel; Luigi Marchionni; Jared S Hierman; Jonathan T Rhodes; Wendy L Devereux; Charles M Rudin; Rex Yung; Giovanni Parmigiani; Marion Dorsch; Craig D Peacock; D Neil Watkins Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701
Authors: Mary C Bedard; Marion G Brusadelli; Adrean Carlile; Sonya Ruiz-Torres; Hannah Lodin; Denis Lee; Matthew Kofron; Paul F Lambert; Adam Lane; Najim Ameziane; El Mustapha Bahassi; Kathryn A Wikenheiser-Brokamp; Alessandro de Alarcon; David F Smith; Susanne I Wells Journal: Viruses Date: 2021-01-06 Impact factor: 5.048
Authors: Mary C Bedard; Alessandro de Alarcon; Yann-Fuu Kou; David Lee; Alexandra Sestito; Angela L Duggins; Marion Brusadelli; Adam Lane; Kathryn A Wikenheiser-Brokamp; Susanne I Wells; David F Smith Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639